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A reference standard calibrated in the International Units is needed for the quality control of hepatitis A
vaccine. Thus, National Institutes for Food and Drug Control launched a project to establish a non-
adsorbed inactivated hepatitis A vaccine reference as the working standard calibrated against the 1st
International Standard (IS). Two national standard candidates (NSCs) were obtained from two manu-
facturers, and designated as NSC A (lyophilized form) and NSC B (liquid form). Six laboratories partici-
pated in the collaborative study and were asked to use their in-house validated enzyme-linked
immunosorbent assay methods to detect hepatitis A vaccine antigen content. Although both exhibited
good parallelism and linear relationship with IS, NSC B showed a better agreement among laboratories
than NSC A. And based on suitability of the candidates, NSC B was selected. The accelerated degradation
study showed that NSC B was stable at the storage temperature (70 C). Therefore NSC B was
approved as the ﬁrst Chinese national antigen standard for inactivated hepatitis A vaccine, with an
assigned antigen content of 70 IU/ml.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis A is an acute infectious disease of liver caused by
hepatitis A virus (HAV) and is mostly transmitted through the fecal-
oral route. It is associated with poor sanitation and particularly
correlated with poverty. HAV, one of the major global public health
threats, is responsible for 1.4 million cases of hepatitis Aworldwide
annually [1]. Vaccination is the most successful and cost-effective
measure to prevent and control HAV. Inactivated hepatitis A vac-
cine Havrix® was ﬁrst developed by Glaxosmithkline in 1992 [2],
followed by Merck Sharp & Dohme Corp (Vaqta®) [3], Sanoﬁ Pas-
teur S.A. (Avaxim®) [4] and Crucell Switzerland AG (Epaxal®) [5,6].
In 2001, Healive®, a preservative-free inactivated HAV vaccineefﬁcients of variations; ELISA,
tis A virus; IS, international
titute of Biological Standards
Drug Control; NSCs, national
control; R&D, research and
od and Drug Control, No. 2,
10 67095357; fax: þ86 10
Ltd on behalf of International Allian
c-nd/4.0/).invented by Sinovac Biotech Co. Ltd., was licensed in China [7]. In
2006, another inactivated vaccine produced by the Chinese Acad-
emy of Medical Sciences is also available in the Chinese market [8].
HAV vaccination has been recommended by the Expanded Pro-
gramme on Immunization and has been administrated to 20
million children annually in mainland China.
The 1st World Health Organization (WHO) International Stan-
dards (IS) for inactivated hepatitis A vaccine (code number: 95/500)
was established in 1999 [9]. However, so far except a non-adsorbed
inactivated HAV as the European working standard calibrated
against the 1st WHO IS in 2010 [10], national standards and other
secondary standards for hepatitis A vaccine were neglected.
Currently, in the Chinese market the dosage units of inactivated
hepatitis A vaccine frommost manufacturers were still determined
using the manufacturer's own internal references expressed as
either u, U, El.U. or EU (Supplemental Table 1), making it difﬁcult to
standardize vaccine quality control (QC). Therefore a national
standard for hepatitis A vaccine is urgently needed in China.
Based on the requirements of the WHO manual for the estab-
lishment of national and other secondary standards for vaccines
[11] and the Chinese Pharmacopoeia (CP, 2010 version) regarding
the preparation of national standards and the calibration of bio-
logical products, a national collaborative study was organized by
the National Institutes for Food and Drug Control, China (NIFDC).ce for Biological Standardization. This is an open access article under the CC BY-NC-
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brated against the current WHO IS in antigen content assays using
in-house ELISA methods. Based on the study results, the ﬁrst Chi-
nese national antigen standard for inactivated hepatitis A vaccine
was established, which would play an important role in vaccine
manufacturing quality control and dosage comparability.
2. Materials and methods
2.1. Participants
A total of six laboratories participated in the study, including
two vaccine manufacturers, three research and development (R&D)
laboratories and one national control laboratory (see Appendix A).
Participants were randomly assigned with aliases from Lab 1 to Lab
6, and not necessarily related to the order of listing.
2.2. International standard (IS)
1st WHO IS for hepatitis A vaccine (inactivated), provided by the
National Institute of Biological Standards and Control (NIBSC, code
number 95/500), with an assigned antigen content of 100 IU/ml,
stored at 20 C.
2.3. National standard candidates (NSCs)
Two HAV bulk materials were included in this study. Candidate
A (NSC A) is a bulk material (batch No. 01-E1312-032) provided by
Sinovac Biotech Ltd (Beijing, China). The HAV strain was TZ84, and
was cultivated in 2BS cell line (human fetal lung diploid ﬁbroblast)
by cell factory technology. It was produced through virus harvest,
trichloromethane extraction, chromatographic puriﬁcation, ultra-
ﬁltration, concentration, and formalin inactivation. This bulk ma-
terial was aliquot into 3000 vials. Themean volumewas 0.59ml per
vial (CV 1.4%). After lyophilization, the vials were closed with
rubber-stoppers, sealed with tear-off aluminum caps, and stored at
20 C. Moisture content was less than 1%. NSC A should be
reconstituted in 0.8 ml puriﬁed water before use. The HAV antigen
content was 57 IU/ml detected against WHO IS by the manufac-
turer's in-house method, and the CV value of antigen content ho-
mogeneity was 8.9%.
Candidate B (NSC B) is a bulk material (batch No. L201208-01)
provided by the Institute of Medical Biology, Chinese Academy of
Medical Sciences (Kunming, China). The HAV strain was L-8, and
was cultivated in KMB17 cell line (human fetal lung diploid ﬁbro-
blast) by cell factory technology. It was produced through virus
harvest, ultraﬁltration, concentration, trichloromethane extraction,
chromatographic puriﬁcation, and formalin inactivation. This bulk
material was aliquot into 3000 vials. They were closed with rubber-
stoppers and sealed with tear-off aluminum caps. NSC B was in
liquid form supplemented with 2.5% bovine serum albumin. The
mean volume was 0.53 ml per vial (CV 2.5%). The vials were stored
at 70 C. The HAV antigen content was 69 IU/ml detected against
WHO IS by the manufacturer's in-house method, and the CV value
of antigen content homogeneity was 6.6%.
2.4. Reagents and methods
ELISAwas awell accepted method to determine antigen content
of inactivated HAV, and was used for the establishment of WHO IS
(95/500) [9]. All participants in this study were asked to use their
own in-house ELISAmethods/reagents to detect HAV antigen in the
collaborative study. All in-house antigenicity assays were per-
formed using sandwich ELISA. In brief, 96-well microtiter plates
were coated with monoclonal antibody against HAV. According tothe linearity range of each ELISA method, plates were incubated
with HAV antigen at appropriate serial dilutions. Detection was
performed using horseradish peroxidase-conjugated polyclonal or
monoclonal secondary antibody, followed by the addition of the
tetramethylbenzidine substrate. The absorbance at 450/630 nm
was measured by an ELISA plate reader.
2.5. Calibration of candidate materials against WHO IS
For the calibration of the candidate materials, each participant
performed at least 6 independent assays. Each assay included the
WHO IS and the two NSCs, freshly reconstituted or thawed. At least
four dilutions were required per sample and each dilution was
performed in duplicates for each independent assay. Participants
were requested to report both raw data (Optical Density, 450/
630 nm) and calculated results for HAV antigen content.
2.6. Suitability study
To assess the suitability of the candidates as standards for an-
tigen bulks, there were nine samples included in this study. Sam-
ples 1e4 were formalin inactivated HAV antigen (non-adsorbed)
bulks from different manufacturers or institutes developing HAV
vaccine and Samples 5e9 were ﬁnal HAV (aluminum adjuvanted)
inactivated vaccines in China. In order to simulate the real situation,
each laboratory (Lab 2,3,4,6) tested HAV bulks produced by them-
selves (samples 1e4) using their in-house ELISA methods. Antigen
contents of Samples 1e4 were expressed against WHO IS, NSC A
and NSC B, respectively. Each participant performed six indepen-
dent assays, and was requested to report both raw data (Optical
Density, 450/630 nm) and calculated results. To evaluate hepatitis A
vaccine ﬁnal products (Samples 5e9), desorption step was needed
before antigenicity assays. However the desorption protocols were
manufacturer-speciﬁc and manufacturers do not wish their
desorption methods disclosed to others. Therefore only Lab 1 was
able to perform the tests (three independent assays per sample) on
the ﬁnal products (Samples 5e9). The antigen contents of these
vaccines were individually expressed against WHO IS and NSC B
after appropriated desorption step. The details of these samples are
shown in Table 1.
2.7. Stability studies
Accelerated degradation studies were carried out to analyze the
stability of NSC B. Sample vials were stored at 150 C, 70 C,
20 C, þ4 C and þ25 C for a period of 0.5e12 months. The an-
tigen contents of vials were measured against WHO IS by Lab 1
using its in-house ELISA method. Vials at all temperature and
storage time points were evaluated in quadruplicates in two in-
dependent assays. The vials stored at 70 C (incubated for 0 day)
were used as baseline and the degradation rate of antigen content
was calculated for each temperature. The baseline (69.4 IU/ml) was
obtained from the result of antigen content homogeneity detected
by the same in-house ELISA method as above.
For the freezeethaw stability, the antigen content of NSC B with
3, 6, 9, 12 and 14 freezeethaw cycles was expressed against that
fromvials without freezeethaw cycle, which was assumed as 70 IU/
ml. Vials with all freezeethaw cycles were evaluated in duplicate in
two independent assays.
2.8. Statistical analysis
The raw data was submitted to NIFDC and analyzed using the
statistical software package “statistical analysis”. The parallel line
model was applied to analyze the log-transformation
Table 1
Sample information.
Sample code Description
Sample 1 Hepatitis A virus bulk, produced by Lab 2. Liquid preparation of puriﬁed, formalin-inactivated, and non-adsorbed HAV Storage temp, 4 C.
Sample 2 Hepatitis A virus bulk, produced by Lab 3. Liquid preparation of puriﬁed, formalin-inactivated, and non-adsorbed HAV. Storage temp, 4 C.
Sample 3 Hepatitis A virus bulk, produced by Lab 4. Liquid preparation of puriﬁed, formalin-inactivated, and non-adsorbed HAV. Storage temp, 4 C.
Sample 4 Hepatitis A virus bulk, produced by Lab 6. Liquid preparation of puriﬁed, formalin-inactivated, and non-adsorbed HAV. Storage temp, 4 C.
Sample 5 Inactivated hepatitis A vaccine with aluminum hydroxide adsorption, ﬁnal product, commercially available. Each 2 ml glass vial contained
0.5 ml of solution. Storage temp, 4 C.
Sample 6 Inactivated hepatitis A vaccine with aluminum hydroxide adsorption, commercially available. Each 2 ml glass vial contained 0.5 ml of solution.
Storage temp, 4 C.
Sample 7 Inactivated hepatitis A vaccine with aluminum hydroxide adsorption, researching and developing, not commercially available. Each 2 ml glass
vial contained 0.5 ml of solution. Storage temp, 4 C.
Sample 8 Inactivated hepatitis A vaccine with aluminum hydroxide adsorption, researching and developing, not commercially available. Each 2 ml glass
vial contained 0.5 ml of solution. Storage temp, 4 C.
Sample 9 Inactivated hepatitis A vaccine with aluminum hydroxide adsorption, commercially available. Each 2 ml glass vial contained 0.5 ml of solution.
Storage temp, 4 C.
HAV: hepatitis A virus.
Table 2
Results of the calibration of candidate materials against WHO IS.
Laba National standard candidate A National standard candidate B
Nb Antigen contents (IU/ml) CVc (%) N Antigen contents (IU/ml) CV (%)
1 6 58.4 3.4 6 73.0 7.7
2 6 58.8 12.9 6 65.7 4.2
3 6 49.2 10.9 6 66.8 12.7
4 6 46.3 9.5 6 73.5 5.4
5 6 59.1 11.2 6 70.3 8.3
6 6 40.1 7.1 6 70.9 7.1
Inter-lab CVd (%) 15.5 4.6
Overall antigen contents (IU/ml) 51.4 70.0
95% CLe (% of antigen contents) ±12.4 ±3.7
a Lab ¼ laboratory code.
b N ¼ assay number.
c CV (%) ¼ intra-laboratory variability.
d Inter-lab CV (%) ¼ inter-laboratory variability.
e 95% CL ¼ 95 percent conﬁdence limit.
F. Gao et al. / Biologicals 44 (2016) 198e205200transformated relative OD values (Optical Density, 450/630 nm) of
the raw data. Results from each assay reported as ‘invalid’ at a 5%
signiﬁcance level for non-parallelism or non-linearity were
excluded. Parallelism and linearity were analyzed by multiple
parallel line comparison. The statistical validity was assessed by
analysis of variance tests. When F value < F(DF,n)0.05, it indicates
that P value > 0.05, and there was no signiﬁcant deviation from
linearity and parallelism between two lines. When F
value  F(DF,n)0.05, it indicates that P value < 0.05 and there was
signiﬁcant deviation from linearity and parallelism between two
lines. If proved to be valid, the relative HAV antigen content couldFig. 1. The distribution of antigen content relative to IS. A, histograms of antigen content est
using NSC B as the standard (IU/ml). Lab 1e6 represent six individual participants.be estimated. However, estimated antigen content with associated
95 percent conﬁdence limits out of 80e120 percent was rejected
even if there were no signiﬁcant deviations from linearity and/or
parallelism. Combined antigen contents were obtained by taking
geometric mean of results from all assays from each laboratory, and
overall antigen contents were calculated as geometric means of
results from all laboratories. The antigen contents were expressed
with 95% conﬁdence limit. Estimates of intra-laboratory and inter-
laboratory variability were expressed as the coefﬁcients of varia-
tions (CV %) of antigen content estimates. Total 144 data sets
returned to NIFDC, and no data were rejected.imated using NSC A as the standard (IU/ml). B, histograms of antigen content estimated
F. Gao et al. / Biologicals 44 (2016) 198e205 2013. Results
3.1. Quality control of bulk materials of national standard
candidates
Quality control of bulk materials of NSCs regarding HAV antigen
content, protein content, protein identiﬁcation, sterility, virus
inactivation, residual bovine serum albumin has been performed
and met the speciﬁcations of CP 2010. The results are shown in
Supplemental Table 2.Fig. 2. Suitability of hepatitis A antigen standards. The HAV antigen contents in Samples 1e
parallelism and linearity results of Sample 1 detected by Lab 2 using its internal in-house me
using its internal in-house method. GeI, representative parallelism and linearity results o
parallelism and linearity results of Sample 4 detected by Lab 6 using its internal in-house me
the statistical validity was assessed by analysis of variance tests. All data of parallelism and3.2. Calibration of candidates against IS
All participants used their own in-house validated ELISA
methods to measure HAV antigen in the collaborative study. All
data submitted from six laboratories met the validation acceptance
criteria consisting of tests of parallelism, linearity and 95 percent
conﬁdence limits. All laboratories carried out six independent as-
says with NSC A and NSC B against WHO IS. The results are shown
in Table 2 and Fig. 1. Intra-laboratory variability of NSC A ranged
from 3.4% to 12.9%, and intra-laboratory variability of NSC B ranged4 were expressed against WHO IS, NSC A and NSC B, respectively. AeC, representative
thod. DeF, representative parallelism and linearity results of Sample 2 detected by Lab 3
f Sample 3 detected by Lab 4 using its internal in-house method. JeL, representative
thod. Parallelism and linearity were analyzed by multiple parallel line comparison and
linearity showed P > 0.05.
Table 3
Results of the suitability study for hepatitis A virus bulks.
Standards Value
assignment
Antigen contents (IU/ml)
[95% CLb (% of antigen contents)]
Sample 1
(ratioc)
Sample 2
(ratio)
Sample 3
(ratio)
Sample 4
(ratio)
WHO ISa 100 IU/ml 1837 [±3]
N/Ad
Ne ¼ 6
48 [±19]
N/A
N ¼ 6
105 [±8]
N/A
N ¼ 6
55 [±6]
N/A
N ¼ 6
NSC A 51 IU/ml 1465 [±8]
(0.797)
N ¼ 6
56 [±15]
(1.167)
N ¼ 6
125 [±7]
(1.190)
N ¼ 6
68 [±4]
(1.236)
N ¼ 6
NSC B 70 IU/ml 1801 [±3]
(0.980)
N ¼ 6
54 [±11]
(1.125)
N ¼ 6
105 [±6]
(1.000)
N ¼ 6
52 [±6]
(0.945)
N ¼ 6
a WHO IS ¼World Health Organization international standards.
b 95% CL ¼ 95 percent conﬁdence limit.
c Ratio ¼ ratio between NSCs and IS.
d N/A ¼ not available.
e N ¼ assay number.
F. Gao et al. / Biologicals 44 (2016) 198e205202from 4.2 to 12.7%. Inter-laboratory variability of NSC A and B was
15.5% and 4.8%, respectively. The overall geometric mean of all
pooled results was 51.4 IU/ml (±12.4%) for NSC A, and 70.0 IU/ml
(±3.7%) for NSC B.
3.3. Suitability of the candidates as national standards
In order to ensure that the national standards can be used in
different laboratories with different in-house methods, Lab 2,3,4,6
carried out six assays with their own HAV antigen bulks (Samples
1e4) against the WHO IS, NSC A and B, respectively. As shown in
Fig. 2, Samples 1e4 were all in good parallelism and linear re-
lationships with WHO IS, NSC A and B using respective in-house
methods (P > 0.05), suggesting that the two candidate antigen
standards possessed good suitability. In addition, WHO IS was
100 IU/ml, NSC A was 51 IU/ml and NSC B was 70 IU/ml, respec-
tively. The antigen contents of Samples 1e4 were 56 IU/ml to
1465 IU/ml, 52 IU/ml to 1801 IU/ml, and 48 IU/ml to 1837 IU/ml
when using NSC A, NSC B, and WHO IS as the reference, respec-
tively. The ratios between the antigen contents of Samples 1e4
expressed against NSC A and those expressed against WHO IS were
from 0.797 to 1.236. For NSC B, the ratios were from 0.945 to 1.125
(Table 3). Obviously, when using NSC B as the reference, the
observed antigen contents were more consistent with values ob-
tained using WHO IS as the reference.
Based on the results of the calibration and suitability test of HAV
bulks, NSC B was considered more appropriate than NSC A to be
established as the national standard. Therefore, only NSC B was
employed as a reference for the suitability test of the ﬁnal products.
According to the desorption protocols of each manufacturer, the
aluminum hydroxide of Samples 5e9 was removed from HAV an-
tigens. Lab 1 performed 3 independent assays and expressed the
antigen content of Samples 5e9 against the WHO IS and NSC B,
respectively. Obviously, both WHO IS and NSC B had good paral-
lelism and linear relationships with the ﬁnal products (P > 0.05)
(Fig. 3). The antigen contents of Samples 5e9 ranged from 30 IU/ml
to 62 IU/ml, and 30 IU/ml to 63 IU/m when calculated using NSC B
and WHO IS as the reference, respectively. The ratios between an-
tigen contents against NSC B and those against WHO IS were from
0.98 to 1.03 (Table 4).
3.4. Stability studies
For accelerated degradation study, NSC B stored at 150 C,
70 C, 20 C, þ4 C and þ25 C for a period of 0.5e12 monthswere determined against WHO IS using the in-house method by
Lab 1. The results are shown in Table 5. Good stability was observed
at all temperatures except20 C for each time points, with 49.1 IU/
ml for 0.5 month, and 30.7 IU/ml for 1 month. Surprisingly, there
was more degradation at 20 C than at higher temperatures, such
as þ4 C and þ25 C.
For freezeethaw stability (Table 6), the antigen contents of NSC
B after 3,6,9,12 and 14 freezeethaw cycles were analyzed concur-
rently, and were expressed against the vials without freezeethaw
cycle (70 IU/ml, assumed). The degradation rates were 1%, 5%, 6%,
3.4% and 4.4%, respectively.
4. Discussion
In the present study, both NSC A and NSC B were linear and
parallel with WHO IS and the 95% conﬁdence limits of HAV antigen
contents were within 80e120 percent. Variability between labo-
ratories based on the estimates relative to WHO IS was lower for
NSC B than for NSC A by 10.9% (Fig. 1, Table 2). Our results are
consistent with the observation from the original WHO study for
establishment of the 1st IS for HAV. In the original WHO study,
sample A (aqueous) showed lower between laboratory variation
than sample D (freeze-dried). Furthermore, although both NSC A
and B showed good parallelism and linear relationships with
Samples 1e4 (Fig. 2), antigen contents of these samples obtained
when using NSC B as the reference were generally closer to the
estimates relative to WHO IS than those obtained using NSC A as
the reference (Table 3). These results suggest that NSC B is most
suitable to be used as a national standard.
Stability studies showed that NSC B was stable at 25 C for up to
1 month, 4 C for 9 months, and 70 C and 150 C for 12 months
(Table 5). Surprisingly, samples stored at 20 C, were observed
with 30% loss at 0.5 month and >50% loss in antigenicity at 1
month. These results were consistent with those reported by
Stalder et al. [10]. The possible reason for this observation is unclear
and deserves further investigation. NSC B stored at temperature
70 C showed good stability (Table 5) and remained stable after 3
freezeethaw cycles (Table 6).
Based on its better suitability, lower inter-laboratory variability
and better agreement among laboratories, NSC B was approved to
be the 1st Chinese National Standard for inactivated hepatitis A
vaccine (2015 No.0030), with an assigned antigen content of 70 IU/
ml. Storage temperature is recommended to be below70 C. Real-
time stability monitor should be carried out at regular intervals, i.e.
yearly, throughout its shelf time using the vials stored at150 C as
a reference.
Samples 1e4 were puriﬁed HAV bulk antigens from different
manufacturers. In the present study, each sample gave linear and
parallel dose responses with WHO IS and NSC B in the antigenicity
assays (Fig. 2). The potency estimates relative to NSC B were com-
parable to those relative to WHO IS (Table 3). These results sug-
gested that NSC B is suitable to be used as a national standard for
different HAV antigen products.
Since a common desorption method for all hepatitis A vaccines
in Chinesemarket is unavailable, product-speciﬁc reference vaccine
is recommended to be used in each assay. These references are not
calibrated in terms of WHO IS and are expressed in different units.
In order to improve the standardization of the antigenicity assay for
HAV, we evaluated the suitability of the antigen standard as the
reference for ﬁnal vaccine products in the present study. All ﬁve
ﬁnal products (Samples 5e9) were representative vaccines in
China. They were formalin inactivated aluminum adjuvanted HAV
antigens that showed good parallelism and linear relationships
with WHO IS and Chinese national standard (Fig. 3). The estimates
relative to both standards (WHO IS and Chinese national standard)
Fig. 3. The possibility of using antigen as the potency reference for ﬁnal products. Samples 5e9 were ﬁve individual inactivated Hepatitis A vaccines found in China. After
desorption, the HAV antigen contents in Samples 5e9 against WHO IS and NSC B, respectively, were determined. All ﬁve samples were detected by Lab 1 using an in-house method.
AeB, parallelism and linearity results of Sample 5. CeD, parallelism and linearity results of Sample 6. EeF, parallelism and linearity results of Sample 7. GeH, parallelism and
linearity results of Sample 8. IeJ, parallelism and linearity results of Sample 9. Parallelism and linearity were analyzed by multiple parallel line comparison and the statistical validity
was assessed by the analysis of variance tests. All data of parallelism and linearity showed P > 0.05.
Table 4
Results of the suitability study for ﬁnal products.
Standards Value assignment Antigen contents (IU/ml) [95% CLb (% of antigen contents)]
Sample 5
(ratioc)
Sample 6
(ratio)
Sample 7
(ratio)
Sample 8
(ratio)
Sample 9
(ratio)
WHO ISa 100 IU/ml 46 [±8]
N/Ad
Ne ¼ 3
30 [±7]
N/A
N ¼ 3
35 [±6]
N/A
N ¼ 3
37 [±3]
N/A
N ¼ 3
62 [±11]
N/A
N ¼ 3
NSC B 70 IU/ml 46 [±14]
(1.00)
N ¼ 3
30 [±9]
(0.99)
N ¼ 3
34 [±6]
(0.99)
N ¼ 3
37 [±11]
(0.98)
N ¼ 3
63 [±9]
(1.03)
N ¼ 3
a WHO IS ¼World Health Organization international standards.
b 95% CL ¼ 95 percent conﬁdence limit.
c ratio ¼ ratio between NSCs and IS.
d N/A ¼ not available.
e N ¼ assay number.
Table 5
Summary of results from accelerated degradation studies.
Storage period Residual antigen content vs. WHO ISc (IU/ml) Residual antigen content (%)
150 C (95%CLa) 70 C (95%CL) 20 C (95%CL) þ4 C (95%CL) þ25 C (95%CL) 150 C 70 C 20 C þ4 C þ25 C
0 d 69.4
(±2.1)
Nb ¼ 36
100.0
0.5 m /d / 49.1
(±3.0)
N ¼ 4
/ 69.2
(±5.9)
N ¼ 4
/ / 70.8 / 99.7
1 m / / 30.7
(±3.4)
N ¼ 4
/ 77.5
(±8.7)
N ¼ 4
/ / 44.2 / 111.7
6 m / / / 70.8
(±2.3)
N ¼ 4
/ / / / 102.0 /
9 m 70.3
(±1.0)
N ¼ 4
69.6
(±0.7)
N ¼ 4
/ 64.8
(±4.4)
N ¼ 4
/ 101.3 99.9 / 93.4 /
12 m 70.1
(±1.2)
N ¼ 4
69.6
(±2.9)
N ¼ 4
/ / / 101.0 101.9 / / /
a 95%CL ¼ 95 percent conﬁdence limit.
b N ¼ number of vials for test.
c WHO IS ¼World Health Organization international standards.
d / ¼ not tested.
F. Gao et al. / Biologicals 44 (2016) 198e205204were comparable (Table 4), suggesting that the Chinese national
standard is suitable to be used for the calibration of different
product-speciﬁc in-house reference vaccines and these references
could be expressed in the international unit “IU”. Therefore the
Chinese national standard could greatly improve standardization in
HAV vaccine quality control.
It's worth noting that the long-term stability of the aluminum
adsorbed vaccine could be a challenge. Unlike the WHO IS, whichTable 6
Summary of results from freezeethaw stability study.
Freezing and thawing cycle Residual antigen content
0 70 (assumed) Nb ¼ 2
3 69.3 (±4.1) N ¼ 2
6 66.5 (±2.7) N ¼ 2
9 65.8 (±6.9) N ¼ 2
12 67.6 (±4.8) N ¼ 2
14 66.9 (±2.1) N ¼ 2
a 95%CL ¼ 95 percent conﬁdence limit.
b N ¼ assay number.
c N/A ¼ not available.has shown to be stable over 16 years storage at 70 C [12], three
product-speciﬁc European Pharmacopoeia Biological Reference
Preparations established in 1998 had to be withdrawn due to drop
in the antigen content through the routine monitoring [13]. These
reference preparations were aqueous preparations of inactivated
HAVs adsorbed onto aluminum. Since they could not be stored
frozen, the antigens without absorption to aluminum would be
more stable. However, using the antigen standard directly in the(IU/ml) (±95%CLa) Residual antigen content (%)
N/Ac
99.0
95.0
94.0
96.6
95.6
F. Gao et al. / Biologicals 44 (2016) 198e205 205potency assay may not be feasible currently. Despite the linear
relationship and good parallelism between the national standard
and ﬁnal vaccines, the desorption recovery rate of ﬁnal vaccines
could result in lower estimates of potency because the antigen
standard does not need desorption. And the antigen standard will
not be adsorbed in the sameway as is done by eachmanufacturer. If
there is a need to assay a batch of vaccine after mistreatment to see
if it retains potency or if the shelf life can be extended, the results
need to be treated cautiously. It is unclear whether a conversion
factor can be established for each vaccine product and whether
other approach could become available. Therefore, the antigen
standard controls the assays only after desorption for ﬁnal prod-
ucts. Furthermore, due to the fact that different manufacturers in
China use different in-house methods and internal references, the
dosage units for each ﬁnal product are not comparable. In the near
future, we hope that this national antigen standard will be able to
serve as the in vitro relative potency reference to explore the pos-
sibility of dosage comparability in China.
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